• Change in Mean Number of Alcoholic Drinks Consumed Per Day [ Time Frame: Baseline week and Week 2 of the treatment phase ]
  Change in the self-reported average daily consumption over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.
• Number of Participants With Adverse Events [ Time Frame: Through study completion, an average of 3 weeks ]
  Safety assessment via device-related adverse events

• OCDS score [ Time Frame: 3 weeks ]
  Change in the obsessive compulsive drinking scale (OCDS) score
• Adverse Events [ Time Frame: 3 weeks ]
  Safety assessment via device-related adverse events

• Decrease in Mean Alcohol Craving Intensity [ Time Frame: Baseline week and Week 2 of the treatment phase ]
  Change in self-reported average alcohol craving intensity via 100-mm visual-analog scale (VAS). The VAS has a minimum score of 0 (no craving) and a maximum score of 100 (severe craving). We compared the average daily craving intensity over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.
• Usability [ Time Frame: Study completion, at approximately 3 weeks ]
  System Usability Scale (SUS) survey to evaluate usability. The SUS is a 10-item self-report survey (each question is answered on a 5-point Likert scale) which measures usability. An SUS score of 68 is considered average, whereas SUS=80 is the 90th percentile score ("excellent").

• No Intervention: Baseline
  For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
• Experimental: Active treatment
  Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
  Intervention: Device: Empower Neuromodulation System

Inclusion Criteria:

• Is male or female ≥ 21 year of age at Visit 1
• Has a current diagnosis of alcohol use disorder per DSM-5 by clinician assessment
• Endorses Criterion 4 in DSM-5
• Has a desire to maintain abstinence or, if not abstinent, a desire to reduce or quit alcohol use
• Has a breath alcohol concentration of 0.00% at enrollment
• Is able to provide informed consent
• Is able to understand spoken and written English
• Is capable and willing to follow all study-related procedures

Exclusion Criteria:

• Has been diagnosed with unstable psychosis, epilepsy, peripheral neuropathy, or nerve damage
• Requires acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD)
• Has implanted electrical and/or neurostimulator device (e.g. pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator, bone growth stimulator, or cochlear implant)
• Has an electrically conductive metal object (e.g. jewelry) that cannot be removed from the palm and will directly contact the gel electrodes of the Empower Neuromodulation System
• Will not, for the duration of the participation in the study, have a living situation that provides regular access to an electrical outlet.
• Is pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
• Has used an investigational drug/device therapy within the past 4 weeks
• Is deemed unsuitable for enrollment in the study by the PI

• National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Northern California Institute of Research and Education